Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
BeyondSpring Inc. (BYSI) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/04/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"BeyondSpring Inc."
07/14/2023 6-K Quarterly results
05/12/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
04/18/2023 6-K Quarterly results
03/14/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
02/28/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
02/24/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
01/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"BeyondSpring Inc."
12/30/2022 6-K Quarterly results
11/23/2022 6-K Quarterly results
08/29/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
06/13/2022 6-K Quarterly results
06/09/2022 6-K Quarterly results
04/22/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
01/11/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Press Release"
12/30/2021 6-K Quarterly results
Docs: "FORM 6-K",
"BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update"
12/27/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
12/01/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia"
11/10/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"BeyondSpring Appoints Commercial Leader Mark Santos to its Board of Directors"
09/21/2021 6-K Quarterly results
09/10/2021 6-K Quarterly results
08/26/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"BeyondSpring Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater China"
08/05/2021 6-K Quarterly results
08/04/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"BeyondSpring Announces Positive Topline Results from"
07/14/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney"
06/16/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"NEW YORK, Jun. 16, 2021 – BeyondSpring Inc."
04/01/2021 6-K Quarterly results
03/19/2021 6-K Quarterly results
03/16/2021 6-K Quarterly results
02/09/2021 6-K Quarterly results
12/18/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"NEW YORK – December 17, 2020"
11/23/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Underwriting Agreement, by and between the Company, BofA Securities, Inc., Jefferies LLC and Evercore Group L.L.C., as representatives of the underwriters named therein",
"Opinion of Maples and Calder (Hong Kong) LLP"
11/17/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"NEW YORK, November 17, 2020 – BeyondSpring Inc."
11/16/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"BeyondSpring Announces Positive Topline Results from its PROTECTIVE-2 Phase 3 Registrational Trial of Plinabulin in Combination with Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy